Ono Pharmaceutical Co., Ltd. (OPHLF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
OPHLF steht fuer Ono Pharmaceutical Co., Ltd., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0). Die Aktie erzielt 59/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 15. März 2026Ono Pharmaceutical Co., Ltd. (OPHLF) Gesundheitswesen & Pipeline-Uebersicht
Ono Pharmaceutical Co., Ltd., established in 1717, develops and markets pharmaceutical products and diagnostic reagents globally. With a diverse portfolio spanning oncology, diabetes, and immunology, the company maintains a strong presence in the healthcare sector, supported by collaborations and a robust pipeline, and currently has a market capitalization of $6.58 billion.
Investmentthese
Ono Pharmaceutical presents a compelling investment case based on its established market presence, diverse product portfolio, and strategic collaborations. With a P/E ratio of 17.79 and a profit margin of 12.3%, the company demonstrates financial stability. Growth catalysts include the expansion of existing product lines like Opdivo and Forxiga, as well as the development of new therapies in its pipeline. The company's dividend yield of 3.39% offers an attractive return for investors. However, potential risks include regulatory hurdles, competition from other pharmaceutical companies, and the inherent uncertainties of drug development. The company's beta of 0.10 suggests low volatility compared to the overall market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market capitalization of $6.58 billion indicates substantial company size and investor confidence.
- P/E ratio of 17.79 suggests a reasonable valuation compared to earnings.
- Profit margin of 12.3% demonstrates the company's ability to generate profit from its revenue.
- Gross margin of 69.8% reflects efficient cost management in the production and sales of pharmaceuticals.
- Dividend yield of 3.39% provides a steady income stream for investors.
Wettbewerber & Vergleichsunternehmen
Staerken
- Innovative drug pipeline
- Strong market position in Japan
- Strategic collaborations with leading research institutions
- Diverse product portfolio
Schwaechen
- Reliance on a few key products
- Limited presence in some emerging markets
- Exposure to generic competition
- OTC listing may limit access to capital
Katalysatoren
- Upcoming: Clinical trial results for novel therapies in the pipeline.
- Upcoming: Regulatory approvals for new indications of existing drugs.
- Ongoing: Expansion of strategic collaborations and partnerships.
- Ongoing: Increasing demand for pharmaceutical products in emerging markets.
- Ongoing: Development of digital health solutions to improve patient outcomes.
Risiken
- Potential: Regulatory changes and pricing pressures could impact revenue.
- Potential: Competition from other pharmaceutical companies could erode market share.
- Potential: Patent expirations could lead to generic competition.
- Ongoing: The inherent uncertainties of drug development could result in clinical trial failures.
- Ongoing: Economic downturns could reduce demand for pharmaceutical products.
Wachstumschancen
- Expansion of Opdivo's Indications: Ono Pharmaceutical has the opportunity to expand the approved indications for Opdivo, its leading oncology drug. This includes pursuing approvals for new cancer types and combination therapies. The global oncology market is projected to reach $286.6 billion by 2031, providing a substantial market for Opdivo's continued growth. Timeline: Ongoing clinical trials and regulatory submissions.
- Development of Novel Therapies: Ono Pharmaceutical's pipeline includes several promising drug candidates targeting various diseases, including autoimmune disorders, neurological conditions, and other cancers. Successful development and commercialization of these therapies could significantly boost revenue. The market for autoimmune disease treatments is expected to reach $150 billion by 2028. Timeline: Clinical trials in progress with potential launches in the next 3-5 years.
- Strategic Collaborations and Acquisitions: Ono Pharmaceutical can pursue strategic collaborations and acquisitions to expand its product portfolio and geographic reach. Partnering with biotech companies and research institutions can accelerate drug development and access new technologies. The company's existing collaborations with Adimab LLC and Turbine Ltd. demonstrate its commitment to this strategy. Timeline: Ongoing, with potential deals announced in the next 1-2 years.
- Geographic Expansion: Ono Pharmaceutical can expand its presence in emerging markets, such as China and India, where there is a growing demand for pharmaceutical products. This includes establishing local manufacturing facilities and distribution networks. The pharmaceutical market in emerging economies is expected to grow at a faster rate than developed markets. Timeline: Gradual expansion over the next 5-10 years.
- Digital Health Integration: Ono Pharmaceutical can leverage digital health technologies, such as telemedicine and mobile health apps, to improve patient outcomes and enhance its market reach. This includes developing digital therapeutics and remote monitoring solutions. The digital health market is projected to reach $660 billion by 2028. Timeline: Pilot programs and partnerships in the next 2-3 years, followed by broader implementation.
Chancen
- Expansion into new therapeutic areas
- Increased demand for pharmaceutical products in emerging markets
- Development of personalized medicine
- Leveraging digital health technologies
Risiken
- Regulatory changes and pricing pressures
- Competition from other pharmaceutical companies
- Patent expirations
- Economic downturns
Wettbewerbsvorteile
- Patented pharmaceutical products provide market exclusivity.
- Strong brand reputation in key therapeutic areas.
- Established relationships with healthcare providers and distributors.
- Extensive research and development capabilities.
Ueber OPHLF
Ono Pharmaceutical Co., Ltd. is a global pharmaceutical company headquartered in Osaka, Japan, with a history stretching back to its founding in 1717. Initially a pharmaceutical wholesaler, the company transitioned to research and development, focusing on innovative drugs. Today, Ono Pharmaceutical develops, manufactures, and markets a wide range of pharmaceutical products and diagnostic reagents across several therapeutic areas, including oncology, diabetes, immunology, and neurology. Key products include Opdivo, an intravenous infusion for malignant tumors, and Glactiv, a tablet for type 2 diabetes. The company also offers treatments for chemotherapy-induced nausea, pheochromocytoma, and other conditions. Ono Pharmaceutical has expanded its global reach through strategic collaborations with companies like Adimab LLC, Turbine Ltd., Sibylla Biotech and academic institutions such as Harvard University. These collaborations enhance its research and development capabilities, allowing it to explore new therapeutic targets and technologies. The company's commitment to innovation and patient care has solidified its position as a key player in the pharmaceutical industry.
Was das Unternehmen tut
- Develops and markets pharmaceutical products and diagnostic reagents.
- Offers prescription drugs for oncology, diabetes, immunology, and neurology.
- Conducts research and development to discover new therapeutic targets.
- Manufactures pharmaceutical products in compliance with regulatory standards.
- Collaborates with other companies and research institutions to accelerate drug development.
- Distributes its products globally through a network of distributors and partners.
- Provides patient support programs to improve adherence and outcomes.
Geschaeftsmodell
- Develops and patents innovative pharmaceutical products.
- Generates revenue through the sale of prescription drugs.
- Invests in research and development to create new products.
- Partners with other companies to expand its product portfolio and geographic reach.
Branchenkontext
Ono Pharmaceutical operates within the global pharmaceutical industry, a sector characterized by intense competition, stringent regulations, and high research and development costs. The market is driven by an aging population, increasing prevalence of chronic diseases, and technological advancements in drug discovery. Ono Pharmaceutical competes with major pharmaceutical companies, including DSRLF (Daiichi Sankyo), FLMNF (Fuji Pharma), GZPHF (Guangzhou Baiyunshan Pharmaceutical), HKMPF (Lee's Pharmaceutical), and HKMPY (Hutchison Medipharma), all vying for market share in key therapeutic areas. The company's focus on innovative therapies and strategic collaborations positions it to capitalize on the growing demand for advanced medical treatments.
Wichtige Kunden
- Hospitals and clinics
- Pharmacies
- Patients with various medical conditions
- Healthcare providers
Finanzdaten
Chart & Info
Ono Pharmaceutical Co., Ltd. (OPHLF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
businesswire.com · 2. März 2026
-
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
businesswire.com · 17. Feb. 2026
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer OPHLF.
Kursziele
Wall-Street-Kurszielanalyse fuer OPHLF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von OPHLF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Aktuelle Nachrichten
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
OPHLF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ono Pharmaceutical may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. This can result in increased risks for investors due to the potential for less transparency and greater information asymmetry.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure
- Lower trading volume and liquidity
- Potential for price manipulation
- Increased regulatory scrutiny
- Higher risk of fraud or mismanagement
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Review the company's investor relations materials and communications.
- Check for any news articles or reports about the company's activities.
- Consult with a financial advisor before investing.
- Established history dating back to 1717
- Global presence and partnerships
- Diverse product portfolio
- Focus on research and development
- Market capitalization of $6.58 billion
Ono Pharmaceutical Co., Ltd. Aktie: Wichtige Fragen beantwortet
What are the key factors to evaluate for OPHLF?
Ono Pharmaceutical Co., Ltd. (OPHLF) currently holds an AI score of 59/100, indicating moderate score. Key strength: Innovative drug pipeline. Primary risk to monitor: Potential: Regulatory changes and pricing pressures could impact revenue.. This is not financial advice.
How frequently does OPHLF data refresh on this page?
OPHLF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven OPHLF's recent stock price performance?
Recent price movement in Ono Pharmaceutical Co., Ltd. (OPHLF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative drug pipeline. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider OPHLF overvalued or undervalued right now?
Determining whether Ono Pharmaceutical Co., Ltd. (OPHLF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying OPHLF?
Before investing in Ono Pharmaceutical Co., Ltd. (OPHLF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding OPHLF to a portfolio?
Potential reasons to consider Ono Pharmaceutical Co., Ltd. (OPHLF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Innovative drug pipeline. Additionally: Strong market position in Japan. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of OPHLF?
Yes, most major brokerages offer fractional shares of Ono Pharmaceutical Co., Ltd. (OPHLF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track OPHLF's earnings and financial reports?
Ono Pharmaceutical Co., Ltd. (OPHLF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for OPHLF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Financial data is based on available information and may be subject to change.
- OTC market data may be limited or incomplete.
- AI analysis is pending and will provide further insights.